Patients with BCR::ABL1-positive CML with IM resistance usually respond to second- or third-generation TKIs such as dasatinib, nilotinib, or ponatinib, but this depends on the patient characteristics and the type of KD mutation present [30,31,35-37]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.